文献速递流行病学与生物统计真实世界研究与卫生经济

中低收入国家基层医疗抗生素处方实践:系统综述与荟萃分析

Antibiotic prescription practices in primary care in low- and middle-income countries: A systematic review and meta-analysis.
PubMed 文献 · PLoS Med · 2020-06-16

该系统综述与荟萃分析纳入27个中低收入国家的48项研究,估算基层医疗抗生素处方合并患病率为52%(95%CI:51%-53%),预测区间44%-60%。仅9项研究评估合理性,不适当处方比例范围8%-100%。16项研究中12国Access组抗生素占比超60%。

要点

  • 中低收入国家基层医疗抗生素处方合并患病率为52%(95%CI:51%-53%)。
  • 仅9项研究评估处方合理性,不适当处方比例范围8%-100%。
  • 16项研究中12国Access组抗生素占总处方超60%。

核心结论

  • 中低收入国家基层医疗抗生素处方率高达52%,不适当使用真实程度因方法学局限无法确定。
  • 亟需将WHO治疗建议和AWaRe分类纳入国家指南以改善处方实践。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase、Global Health和CENTRAL 2010年1月1日至2019年4月4日文献,后更新PubMed至2020年3月11日,无语言限制。
  • 纳入27个中低收入国家的48项报告基层医疗用药数据的研究,多数来自公共部门和城市地区,主要基于病历摘录和/或处方审计。
  • 采用随机效应模型进行荟萃分析,使用修改版Hoy工具评估偏倚风险,按WHO AWaRe框架分类抗生素。

主要发现

  • 抗生素处方合并患病率为52%(95%CI:51%-53%),预测区间44%-60%,各研究估计值在不同场景间一致。
  • 仅9项研究评估合理性,不同疾病患者中不适当处方比例范围为8%至100%。
  • 16项来自15个国家报告抗生素细节的研究中,12个国家Access组抗生素占总处方超60%。

关键数值与推荐

  • 抗生素处方合并患病率52%(95%CI:51%-53%),预测区间44%-60%。
  • 不适当处方比例范围8%-100%(仅9项研究评估合理性)。
  • 12个国家Access组抗生素占总处方超60%(共16项研究来自15个国家)。

临床怎么用

  • 应推动将WHO治疗建议和AWaRe分类整合入国家指南以规范基层抗生素处方。
  • 需针对中低收入国家基层医疗开展紧急行动改善处方实践。

局限性

  • 合并估计的解释受研究间显著异质性限制。
  • 多数可用研究存在方法学问题,报告细节不足难以评估处方合理性。
  • 研究多来自公共部门和城市地区,代表性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The widespread use of antibiotics plays a major role in the development and spread of antimicrobial resistance. However, important knowledge gaps still exist regarding the extent of their use in low- and middle-income countries (LMICs), particularly at the primary care level. We performed a systematic review and meta-analysis of studies conducted in primary care in LMICs to estimate the prevalence of antibiotic prescriptions as well as the proportion of such prescriptions that are inappropriate. METHODS AND FINDINGS: We searched PubMed, Embase, Global Health, and CENTRAL for articles published between 1 January 2010 and 4 April 2019 without language restrictions. We subsequently updated our search on PubMed only to capture publications up to 11 March 2020. Studies conducted in LMICs (defined as per the World Bank criteria) reporting data on medicine use in primary care were included. Three reviewers independently screened citations by title and abstract, whereas the full-text evaluation of all selected records was performed by 2 reviewers, who also conducted data extraction and quality assessment. A modified version of a tool developed by Hoy and colleagues was utilized to evaluate the risk of bias of each included study. Meta-analyses using random-effects models were performed to identify the proportion of patients receiving antibiotics. The WHO Access, Watch, and Reserve (AWaRe) framework was used to classify prescribed antibiotics. We identified 48 studies from 27 LMICs, mostly conducted in the public sector and in urban areas, and predominantly based on medical records abstraction and/or drug prescription audits. The pooled prevalence proportion of antibiotic prescribing was 52% (95% CI: 51%-53%), with a prediction interval of 44%-60%. Individual studies' estimates were consistent across settings. Only 9 studies assessed rationality, and the proportion of inappropriate prescription among patients with various conditions ranged from 8% to 100%. Among 16 studies in 15 countries that reported details on prescribed antibiotics, Access-group antibiotics accounted for more than 60% of the total in 12 countries. The interpretation of pooled estimates is limited by the considerable between-study heterogeneity. Also, most of the available studies suffer from methodological issues and report insufficient details to assess appropriateness of prescription. CONCLUSIONS: Antibiotics are highly prescribed in primary care across LMICs. Although a subset of studies reported a high proportion of inappropriate use, the true extent could not be assessed due to methodological limitations. Yet, our findings highlight the need for urgent action to improve prescription practices, starting from the integration of WHO treatment recommendations and the AWaRe classification into national guidelines. TRIAL REGISTRATION: PROSPERO registration number: CRD42019123269.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Sulis G, Adam P, Nafade V, et al. Antibiotic prescription practices in primary care in low- and middle-income countries: A systematic review and meta-analysis. PLoS Med. 2020. PMID: 32544153. doi:10.1371/journal.pmed.1003139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。